FindTrial
Sign In

MD1003 100mg capsule

DRUG3 trials

Sponsors

MedDay Pharmaceuticals SA

Conditions

Multiple Sclerosis

Phase 3

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
NCT02220244
MedDay Pharmaceuticals SAMultiple Sclerosis
Start: 2013-10-31End: 2018-01-31Target: 105Updated: 2017-03-27
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
NCT02220933
MedDay Pharmaceuticals SAMultiple Sclerosis
Start: 2013-10-31End: 2018-01-31Target: 144Updated: 2017-03-27
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
TerminatedNCT02936037
MedDay Pharmaceuticals SAMultiple Sclerosis
Start: 2016-12-31End: 2020-04-23Updated: 2020-11-23

Related Papers

Association Between Neurofilament Light Chain and Real-World Ambulatory Function in Progressive MS.
2026-09-09
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
2020-10-2382 citations
Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS (680)
Neurology2020-04-144 citations
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.
2018-07-0125 citations